Sharafeldin N, Zhou L, Singh P, Crossman DK, Wang X, Hageman L, Landier W, Blanco JG, Burridge PW, Sapkota Y, Yasui Y, Armstrong GT, Robison LL, Hudson MM, Oeffinger K, Chow EJ, Armenian SH, Weisdorf DJ, and Bhatia S
Background: Anthracyclines are highly effective in treating cancer, albeit with increased cardiomyopathy risk. Although risk is attributed to associations with single nucleotide polymorphisms (SNPs), multiple SNPs on a gene and their interactions remain unexamined., Objectives: This study examined gene-level associations with cardiomyopathy among cancer survivors using whole-exome sequencing data., Methods: For discovery, 278 childhood cancer survivors (129 cases; 149 matched control subjects) from the COG (Children's Oncology Group) study ALTE03N1 were included. Logic regression (machine learning) was used to identify gene-level SNP combinations for 7,212 genes and ordinal logistic regression to estimate gene-level associations with cardiomyopathy. Models were adjusted for primary cancer, age at cancer diagnosis, sex, race/ethnicity, cumulative anthracycline dose, chest radiation, cardiovascular risk factors, and 3 principal components. Statistical significance threshold of 6.93 × 10 -6 accounted for multiple testing. Three independent cancer survivor populations (COG study, BMTSS [Blood or Marrow Transplant Survivor Study] and CCSS [Childhood Cancer Survivor Study]) were used to replicate gene-level associations and examine SNP-level associations from discovery genes using ordinal logistic, conditional logistic, and Cox regression models, respectively., Results: Median age at cancer diagnosis for discovery cases and control subjects was 6 years and 8 years, respectively. Gene-level association for P2RX7 (OR: 0.10; 95% CI: 0.04-0.27; P = 2.19 × 10 -6 ) was successfully replicated (HR: 0.65; 95% CI: 0.47-0.90; P = 0.009) in the CCSS cohort. Additional signals were identified on TNIK , LRRK2 , MEFV , NOBOX , and FBN3 . Individual SNPs across all discovery genes, except FBN3 , were replicated., Conclusions: In our study, SNP sets having 1 or no copies of P2RX7 variant alleles were associated with reduced risk of cardiomyopathy, presenting a potential therapeutic target to mitigate cardiac outcomes in cancer survivors., Competing Interests: This study was supported in part by the National Institutes of Health grant R35CA220502 (Dr Bhatia), Leukemia Lymphoma Society TRP grant 6563-19 (Dr Bhatia), the V Foundation grant DT2019-010 (Dr Bhatia), Leukemia and Lymphoma Society Career Development Award LLS 3386-19 (Dr Sharafeldin), and National Marrow Donor Program Be The Match Foundation (Dr Sharafeldin). The Childhood Cancer Survivor Study was supported by the National Cancer Institute grant CA55727 (Dr Armstrong). Support to St. Jude Children’s Research Hospital also was provided by the Cancer Center Support grant CA21765 (Principal Investigator Charles Roberts) and the American Lebanese-Syrian Associated Charities. The Children’s Oncology Group study (Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors; NCT00082745; grant COG-ALTE03N1 [Dr Bhatia]) reported here is supported by the National Clinical Trials Network (NCTN) Operations Center grant U10CA180886; Principal Investigator Doug Hawkins); the NCTN Statistics & Data Center grant U10CA180899 (Principal Investigator Todd Alonzo); the Children’s Oncology Group Chair’s grant U10CA098543 (Principal Investigator Peter Adamson); The COG Statistics & Data Center grant U10CA098413 (Principal Investigator Peter Anderson); the NCI Community Oncology Research Program (NCORP) grant UG1CA189955 (Principal Investigator Brad Pollock); and the Community Clinical Oncology Program (CCOP) grant U10CA095861 (Principal Investigator Brad Pollock), and the St Baldrick’s Foundation through an unrestricted grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 The Authors.)